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Abstract	
The	combination	of	genetic	code	reprogramming	and	mRNA	display	is	a	powerful	approach	
for	the	identification	of	macrocyclic	peptides	with	high	affinities	to	a	target	of	interest.	We	
have	previously	 used	 such	 an	 approach	 to	 identify	 a	 potent	 inhibitor	 (CP2)	 of	 the	human	
KDM4A	and	KDM4C	 lysine	demethylases;	 important	regulators	of	gene	expression.	 	 In	 the	
present	study,	we	have	used	genetic	code	reprogramming	to	synthesise	very	high	diversity	
focused	 libraries	 (>	 1012	 compounds)	 based	 on	 CP2	 and,	 through	 affinity	 screening,	 used	
these	 to	 delineate	 the	 structure	 activity	 relationship	 of	 CP2	 binding	 to	 KDM4A.	 	 In	 the	
course	 of	 these	 experiments	 we	 identified	 a	 CP2	 analogue	 (CP2f-7)	 with	 ~4-fold	 greater	
activity	 than	CP2	 in	 in	vitro	 inhibition	assays.	 	This	work	will	 facilitate	 the	development	of	
more	potent,	selective	inhibitors	of	lysine	demethylases.	
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1.	Introduction	
Peptide	display	methodologies	(phage	display,	mRNA	display,	etc)	are	powerful	tools	for	the	
identification	 of	 peptide	 ligands	 to	 targets	 of	 interest.2	 The	 combination	 of	 genetic	 code	
reprogramming	with	mRNA	display	 is	particularly	useful	 in	 this	 respect,	 since	 it	allows	the	
synthesis	 and	 screening	 of	 very	 diverse	 (in	 excess	 of	 1012	 molecule)	 peptide	 libraries	
containing	 diverse	 chemical	 moieties	 not	 limited	 to	 use	 of	 the	 canonical	 proteinogenic	
amino	acids.	 	One	such	approach	that	has	found	particular	utility	 is	Random	non-standard	
Peptide	 Integrated	Display	 (RaPID),	which	 can	 be	 used	 for	 the	 synthesis	 and	 screening	 of	
libraries	 of	 constrained	 macrocyclic	 peptides	 (which	 often	 exhibit	 greater	 target	 affinity,	
bioactivity	and	biostability	than	their	linear	analogues)	through	the	inclusion	of	two	reactive	
moieties	(commonly	a	chloroacetyl	moiety	at	the	N-terminus	and	the	thiol	of	a	downstream	
cysteine)(Figure	1A).3-7	
JmjC-domain	 containing	 lysine	 demethylases	 (JmjC-KDMs)	 play	 critical	 roles	 in	 gene	
expression	 through	 removal	 of	 methyl	 groups	 from	 histone	 lysine	 residues.8,	 9	 	 These	
enzymes	are	Fe(II)	and	2-oxoglutarate	dependent	oxygenases,	and	whilst	inhibitors	of	these	
enzymes	are	known,	many	are,	in	general,	active	site	metal	chelators	with	poor	selectivity	–	
limiting	 their	 usefulness	 as	 JmjC-KDM	 functional	 probes.10	 	 However,	 we	 recently	 used	
RaPID	screening	to	 identify	a	potent	and	selective	macrocyclic	peptide	 inhibitor	of	histone	
H3	lysine	9	/	lysine	36	(K9/K36)	demethylase	KDM4A-C	termed	CP2.5	
In	 the	 present	 study,	 we	 have	 used	 a	 RaPID	 approach	 to	 identify	 variants	 of	 CP2	 from	
focused	peptide	libraries,	thereby	partially	defining	the	structure-activity	relationship	of	CP2	
with	 respect	 to	 KDM4	 binding.	 	 In	 the	 course	 of	 these	 studies	 we	 have	 identified	 one	
peptide	with	improved	inhibitory	activity	compared	with	the	parental	CP2	peptide,	and	two	
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others	 which	 appear	 to	 be	 cell-penetrating	 peptides.	 	 This	 work	 will	 facilitate	 the	
development	of	more	potent,	selective	inhibitors	of	lysine	demethylases.	
	
Figure	1	–	RaPID	selection	process	and	 library	design.	 	A.	 In	RaPID	selection,	an	initial	
DNA	library	assembled	from	oligonucleotides	(lower)	is	transcribed	in	RNA	(1)	and	then	
translated	 in	 a	 genetically	 reprogrammed	 translation	 reaction,	 such	 that	 each	 cyclic	
peptide	formed	is	covalently	linked	to	its	cognate	mRNA	(2).		This	library	of	peptide-RNA	
fusion	molecules	is	panned	against	a	target	of	interest	(in	this	case	KDM4A)	immobilized	
on	 magnetic	 beads,	 and	 an	 enriched	 DNA	 library	 is	 recovered	 by	 RT-PCR.	 	 B.	 Crystal	
structure	of	CP2	bound	to	KDM4A,	showing	the	conserved	Arg	residue	(green)	extending	
down	into	the	active	site	(PDB	ID:	5LY1).		The	metal	ion	is	indicated	in	purple.		C.		Design	
of	peptide	libraries	for	screening.		Each	library	comprised	an	N-chloroacetylated-tyrosine	
initiator,	 a	 variable	 region	 encoded	 by	 NNK	or	NKN	 codons,	 a	 conserved	 RSG	motif,	 a	
second	 variable	 region,	 a	 Cys	 residue	 for	 cyclization	 and	 a	GSGSGS	 spacer.	 	 Pie	 charts	
show	the	amino	acid	frequency	for	NNK	and	NKN	codons.	
	 5	
	
2.	Results	
The	binding	of	CP2	to	KDM4	has	been	shown	to	 involve	the	formation	of	CP2	into	a	beta-
sheet-like	structure,	in	which	the	side	chain	of	its	R6	residue	extends	into	the	active	site	of	
the	enzyme	(Figure	1B).	During	the	screening	experiments	in	which	CP2	was	identified,	this	
R6	 residue	 was	 part	 of	 a	 conserved	 RSG	 motif	 present	 in	 several	 related,	 and	 active,	
macrocyclic	peptides.5	For	these	reasons,	we	based	our	initial	focused	library	design	around	
this	motif,	 such	that	each	peptide	comprised	the	RSG	motif	 flanked	by	4-5	random	amino	
acids	designated	by	NNK	codons	(N	=	A,	C,	G	or	T;	K	=	T	or	G),	capped	at	the	N-terminus	by	a	
chloroacetylated	L-	or	D-Tyr	and	with	a	Cys	residue	C-terminal	to	the	second	random	region	
to	 induce	macrocyclization	 (Figure	1C),11	 giving	a	 theoretical	 library	diversity	of	6.8	 x	1012	
cyclic	peptides.			
We	 had	 previously	 shown	 that	 an	 analogue	 of	 CP2,	 CP2.3	 (in	 which	 V2	 and	 C14	 are	N-
methylated,	 G8	 is	 substituted	 to	 D-Ala,	 Y12	 is	 substituted	 to	 4-fluoro-Phe	 and	 T13	 is	
substituted	 to	 Pro)	 was	 markedly	 more	 active	 in	 cell	 culture	 assays	 than	 the	 parental	
molecule,	 suggesting	 improved	 cell	 membrane	 permeability.5	 Given	 the	 relatively	 high	
molecular	mass	and	polarity	of	CP2.3,	we	reasoned	that	this	permeability	resulted	not	from	
passive	diffusion	but	 from	a	 cell-penetrating	peptide	 (CPP)-like	mechanism	such	has	been	
observed	 for	 HIV	 Tat	 and	 penetratin	 peptides,	 which	 are	 rich	 in	 positively	 charged	 and	
hydrophobic	amino	acids.12		For	this	reason	we	designed	a	second	focused	library	based	on	
the	 first	 in	 which	 the	 random	NNK	 codons	 were	 substituted	 with	 NKN	 codons	 to	 favour	
incorporation	 of	 hydrophobic	 and	 positively	 charged	 residues	 (Figure	 1C),	 giving	 a	
theoretical	library	diversity	of	4.3	x	109	cyclic	peptides.	
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Following	 5	 rounds	 of	 selection	 against	 bead	 immobilised	 KDM4A,	 each	 library	 was	
sequenced	 to	 identify	 variants	 of	 CP2	 with	 the	 ability	 to	 bind	 KDM4A	 with	 high	 affinity	
(Supplementary	Figures	1	and	2).		Of	these,	many	were	slightly	smaller	than	the	original	CP2	
due	to	the	random	inclusion	of	a	Cys	residue	at	position	12	suggesting	that	the	Y12	and	13T	
residues	 are	 not	 required	 for	 binding,	 in	 agreement	 with	 the	 CP2.KDM4A	 co-crystal	
structure.	 	Many	sequences,	particularly	 from	the	NKN	 library	contained	multiple	Arg	and	
hydrophobic	 residues,	 potentially	 improving	 cell	 membrane	 permeability.	 	 Seven	 such	
focused	 CP2	 peptides	 (CP2f-1-7)	 were	 chosen	 for	 characterization,	 based	 on	 similarity	 to	
know	 CPPs	 and	 relative	 enrichment.	 An	 8th	 peptide	 (CP2f-4R)	 representing	 a	 consensus	
sequence	in	which	all	possible	Arg	residues	(at	positions	3,	5,	6	and	10)	were	included	in	a	
background	 of	 hydrophobic	 residues	 was	 also	 chosen	 for	 further	 study,	 despite	 this	
sequence	not	being	observed	following	selection	(Figure	2).	
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Figure	2	–	Peptides	characterized	 in	the	present	study.	 	A.	Alignment	of	CP2	variants	with	
parental	CP2	peptide.		B.	All	peptides	were	synthesized	with	a	N-terminal	chloroacetyl	group	
and	then	cyclized	to	a	downstream	cysteine	via	a	thioether	(as	indicated	for	the	lowermost	
cTat	peptide).	 	Unlabeled	peptides	were	synthesized	with	a	terminal	cysteine	amide	(using	
rink	 amide	 resin).	 	 Fluorescein	 labelled	 peptides	 were	 synthesized	 with	 a	 terminal	 lysine	
amide	which	was	selectively	coupled	to	Fluorescein	as	indicated	in	the	structure	shown.	
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Each	 of	 these	 peptides	 was	 synthesised	 by	 solid	 phase	 techniques	 with	 or	 without	 a	 C-
terminal	fluorescein	tag	attached	through	the	side	chain	of	a	Lys	residue	downstream	of	the	
cyclizing	 Cys	 residue.	 	 Confocal	 microscopy	 using	 the	 fluorescein-tagged	 molecules	
demonstrated	 diffuse	 cellular	 staining	 for	 two	 of	 these	 peptides,	 CP2f-3	 and	 CP2f-4R,	
comparable	 to	 a	 cyclic	 Tat	 (cTat)	 peptide	 used	 as	 a	 positive	 control,	 albeit	 with	 some	
punctate	 marking	 indicative	 of	 lysosomal	 staining	 (Figure	 3).	 	 Further,	 in	 vitro	 inhibition	
assays	using	the	unlabelled	peptides	demonstrated	binding	and	potent	enzyme	inhibition	of	
both	KDM4A	and	KDM4C	with	IC50	values	in	the	nanomolar	range	(Table	1,	Supplementary	
Table	2	and	Supplementary	Figures	3	and	4).		Most	notably,	CP2f-7	was	more	potent	binder	
and	inhibitor	than	the	original	CP2,	with	an	IC50	of	6.0	nM	with	respect	to	KDM4A	and	2.2	
nM	 with	 respect	 to	 KDM4C.	 	 However,	 despite	 in	 vitro	 inhibition	 and	 evidence	 of	 cell	
membrane	 permeability	 (in	 the	 case	 of	 fluorescein-tagged	 CP2f-3	 and	 -8),	
immunofluorescence	 analysis	 of	 cells	 treated	with	 unlabelled	 CP2f-3,	 CP2f-7	 and	 CP2f-4R	
(the	 two	with	 the	 best	 apparent	membrane	 permeability	 and	 the	most	 potent	 in	 in	 vitro	
Figure	3	–	Confocal	microscopy	of	cells	treated	with	fluorescein-labelled	peptides.	MCF7	
cells	were	 stained	with	 10	µM	each	 indicated	 peptide	 (green),	 and	 counterstained	with	
LysoTracker	Red	DND-99	(red)	and	Hoechst	33342	(blue).	
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inhibition	 assays)	 peptides	 showed	 no	 evidence	 of	 alterations	 in	 histone	 lysine	
demethylation	under	the	conditions	tested,	suggesting	either	inability	of	these	peptides	to	
transit	into	cells	or	to	inhibit	KDM4A	in	the	nucleus	(Figure	4).	
	
Table	 1	 –	 In	 vitro	 KDM4A	 and	 KDM4C	 inhibition,	 peptide	 diffusivity	 and	 lysosomal	
colocalization		for	selected	macrocyclic	peptides	
*IC50	 values	 represent	 the	 mean	 of	 duplicate	 data	 from	 3	 (KDM4A)	 or	 2	 (KDM4C)	
independent	experiments	+/-	standard	error	of	the	mean.		**Mean	of	at	least	10	cells,	
+/-	standard	deviation.		***Pearson’s	r	valued	for	lysosome-peptide	colocalization.	Cell	
based	 activity	 assay	 data	 for	 CP2	 was	 determined	 previously.5	 	 (-)	 Not	 tested	 in	 cell	
based	assay;	(+)	increase	in	H3K9me3	at	highest	concentration	tested.		
	
 
KDM4A	
IC50	(nM)*	
KDM4C	
IC50	(nM)*	
Cell	area		
stained	(%)**	
Lysosomal	
colocalization***	
EC50	
(μM)	
CP2	 41	±	22	 46	±	36	 17.4	±	3.9	 0.38	 >	100
	
CP2f-1	 82	±	40	 154	±	30	 1.7	±	2.5	 -0.14	 -	
CP2f-2	 41	±	20	 55	±	10	 0.8	±	0.6	 -0.17	 -	
CP2f-3	 23	±	10	 23	±	5	 65.3	±	21.3	 0.39	 >50	
CP2f-4	 81	±	30	 151	±	71	 3.4	±	2.2	 -0.14	 -	
CP2f-5	 31	±	10	 23	±	8	 12.1	±	4.1	 -0.21	 -	
CP2f-6	 43	±	20	 22	±	11	 2.9		±	1.0	 -0.17	 -	
CP2f-7	 6	±	2	 2.2	±	0.4	 13.4	±	9.7	 -0.22	 >50	(+)	
CP2f-4R	 615	±	160	 466	±	141	 76.8	±	13.1	 0.65	 >50	
CP2f-3(2MeI)	 11	±	3	 12	±	2	 55.6	±	19.8	 0.57	 >50		
CP2f-3(G8DA)	 15	±	4	 38	±	32	 92.7	±	12.5	 0.41	 >50	
CP2f-3(12MeC)	 34	±	14	 53	±	13	 18.0	±	11.4	 0.54	 >50	
CP2f-3.3	 17	±	6	 27	±	3	 7.4	±	3.7	 0.18	 >50	(+)	
CP2f-4R(G8DA)	 208	±	50	 173	±	1	 97.1	±	3.6	 0.41	 >50	
CP2f-4R(12MeC)	 373	±	87	 164	±	38	 28.2	±	7.9	 0.61	 >50	
CP2f-4R.3	 269	±	90	 65	±	11	 1.2	±	1.1	 -0.16	 >50	
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Given	that	CP2.3	exhibits	markedly	 improved	activity	 in	cell	based	assays	 relative	 to	CP2,5	
we	 next	 attempted	 to	 improve	 the	 activity	 of	 CP2f-3	 and	 CP2f-4R,	 the	 two	 peptides	 that	
appeared	most	 cell-membrane	permeant,	 by	 applying	 to	 these	 two	peptide	modifications	
analogous	 to	 those	 found	 in	 CP2.3.	 	 To	 this	 end,	 4	 additional	 analogues	 of	 CP2f-3	 (2MeI,	
G8DA,	12MeC	and	CP2f-3.3	which	includes	all	3	modifications)	and	3	additional	analogues	of	
CP2f-4R	(G8DA,	12MeC	and	CP2f-4R.3	which	includes	both	modifications)	were	synthesised				
with	 or	 without	 fluorescein	 tags.	 	 Confocal	 microscopy	 using	 the	 fluorescein-tagged	
molecules	demonstrated	diffuse	cellular	staining	for	all	of	the	single	substitution	analogues,	
with	 some	 loss	 of	 intensity	 in	 the	 case	 of	 the	 CP2f-4R(12MeC)	 compound,	 but	 almost	
complete	 inhibition	of	uptake	 in	the	case	of	the	multiply	modified	analogues	CP2f-3.3	and	
CP2f-4R.3	 (Figure	 5).	 	 Notably,	 however,	 fluorescently	 tagged	 CP2.3,	 the	 unlabelled	
analogue	 of	 which	 has	 been	 shown	 to	 be	 active	 in	 cell-based	 assays,	 also	 failed	 to	
demonstrate	significant	cellular	staining	(Figure	5).				
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Figure	4.	Cellular	effects	of	cyclic	peptide	dosing	on	HeLa	cells	overexpressing	KDM4A.	(A,	
B)	 Immunofluorescence	 assay	 measuring	 the	 global	 nuclear	 H3K9me3	 staining	 levels	 of	
HeLa	cells	overexpressing	FLAG-tagged	KDM4A	(average	relative	H3K9me3	fluorescence	±	
SEM	(N	>	50	transfected	cells)	is	plotted	for	all	points).	IOX1	is	used	as	a	positive	control.1	
Representative	data	are	shown		
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In	 vitro	 inhibition	 assays	 using	 the	 unlabelled	 CP2f-3	 and	 CP2f-4R	 peptides	 again	
demonstrated	 potent	 inhibition	 of	 both	 KDM4A	 and	 KDM4C	 with	 the	 2MeI	 and	 G8DA	
modifications	improving	activity	and	12MeC	improving	the	activity	of	CP2f-4R	but	impairing	
the	 activity	 of	 CP2f-3	 (Table	 1).	 	 Both	multiply	modified	 variants,	 CP2f-3.3	 and	CP2f-4R.3,	
were	 more	 active	 that	 the	 corresponding	 parental	 compound.	 	 However,	
immunofluorescence	analysis	of	cells	treated	with	the	unlabelled	peptides	again	showed	no	
clear	evidence	of	alterations	in	histone	lysine	demethylation,	suggesting	that,	in	contrast	to	
CP2/CP2.3,	 the	 alterations	 applied	 to	 CP2f-3	 and	 CP2f-4R	 failed	 to	 improve	 membrane	
permeability.		While	CP2f-7,	the	most	potent	KDM4A	inhibitor	against	recombinant	KDM4A,		
showed	hypermethylation	at	high	concentrations	(>	20 μM),	this	is	likely	due	to	cytotoxicity	
since	 some	 extra-nuclear	 staining	 was	 observed	 and	 cells	 exhibited	 condensed	 nuclei	
(Supplementary	Figure	5),13	together	with	a	clear	concentration	dependent	reduction	in	cell	
numbers	at	>	5	μM,	Supplementary	Fig	6)	
Figure	5	–	Confocal	microscopy	of	cells	treated	with	fluorescein-labelled	peptides.		MCF7	
cells	were	 stained	with	 10	µM	each	 indicated	 peptide	 (green),	 and	 counterstained	with	
LysoTracker	Red	DND-99	(red)	and	Hoechst	33342	(blue).	
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3.	Discussion	and	Conclusions	
In	 the	 present	 study,	 we	 have	 used	 RaPID	 screening	 of	 focused	 libraries	 to	 assess	 the	
structure-activity	relationship	of	the	KDM4A/KDM4C	macrocyclic	peptide	ligand	CP2.	Strong	
preferences	 for	 specific	 amino	 acid	 at	 different	 positions	were	 clearly	 apparent,	with	 the	
randomized	region	between	the	initiating	Y	and	RSG	motif	(positions	2-5)	favouring	aliphatic	
residues	with	some	substitution	of	positively	charged	or	polar	residues	possible	at	positions	
3	 and	 5,	 but	 negatively	 charged	 residues	 strongly	 disfavoured.	 	 Interestingly,	 the	
randomized	region	between	the	RSG	motif	and	the	terminal	Cys	was	generally	truncated	to	
3	 residues	 through	 the	 occurrence	 of	 a	 Cys	 residue	 at	 position	 12,	 with	 the	 resulting	 3	
residues	strongly	favouring	aromatic	residues	at	positions	9	and	11	with	an	aliphatic	residue	
at	position	10,	which	could	be	substituted	with	an	Arg	in	some	cases.	
Comparing	 the	 peptides	 recovered	 from	 the	 selections	 with	 CP2,	 the	 most	 noticeable	
difference	 is	 the	 frequent	 C-terminal	 truncation	 discussed	 above.	 	 	 This	would	 appear	 to	
indicate	 that	 the	Y12	and	13T	residues	of	CP2	are	not	critical	 for	KDM4A/KDM4C	binding.		
However,	 one	 of	 the	 few	 full-length	 peptides	 recovered,	 and	 the	 only	 one	 we	 tested	 in	
enzymatic	 inhibition	 assays,	 CP2f-7	 turned	out	 to	 be	 the	most	 potent	 in	 vitro	 inhibitor	 of	
KDM4A/KDM4C	 yet	 identified,	 and	 CP2	 itself	 was	more	 potent	 than	 the	 seven	 truncated	
peptides	 assayed	 in	 this	 study,	 suggesting	 that	 residues	 12	 and	 13	 are	 important	 for	
inhibitory	 activity	 and	 affinity.	 	 One	 possible	 explanation	 for	 this	 is	 that	 the	 truncated	
sequences	are	slightly	favoured	during	PCR	recovery	following	each	round	of	selection,	and	
that	the	small	differences	in	target	affinity	between	the	truncated	and	full-length	sequences	
during	affinity	selection	are	insufficient	to	off-set	this.	
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By	applying	the	non-canonical	modification	of	CP2.3	to	related	peptides,	the	present	study	
also	provides	information	about	the	effect	of	N-methylation	and	substitution	of	glycine	for	
D-Ala	 in	 the	 RSG	motif.	 	 This	 second	modification	 appears	 to	 always	 improve	 the	 in	 vitro	
activity	 and	binding,	 since	 all	 tested	 variants	 containing	 this	modification	 exhibit	 stronger	
activity	 and	 affinity	 than	 their	 respective	 parental	molecules.	 	 Similarly,	N-methylation	 at	
position	 2	 also	 appears	 to	 generally	 improve	 activity,	 a	 result	 supported	 by	 the	 NNK	 L-
initiated	selection	which	demonstrated	a	strong	preference	for	Pro	at	this	site.	
One	of	the	most	striking	features	about	the	present	work	is	the	lack	of	correlation	between	
apparent	cell	membrane	permeability	using	fluorescein-tagged	peptides	and	cellular	activity	
studies.		Both	CP2f-3	and	CP2f-4R	exhibited	apparent	cellular	uptake	and	in	vitro	enzymatic	
inhibition,	but	had	no	observable	effect	on	global	cellular	lysine	methylation.		Additionally,	
whilst	CP2.3	has	been	shown	to	be	substantially	more	active	than	CP2	in	cell	culture	assays	
of	 KDM4	activity,5	 	 CP2	 and	CP2.3	 both	 exhibited	 only	 very	modest	 cellular	 uptake	when	
tagged	 with	 fluorescein,	 suggesting	 that	 microscopy	 of	 fluorescein-tagged	 CP2.3	 may	
underestimate	 the	 membrane	 permeability	 of	 the	 parental	 molecule.	 	 There	 are	 several	
possible	explanations	for	these	observations:		a)	while	fluorescein	alone	is	non-permeable,	
fluorescein	tagging	may	substantially	affect	the	properties	of	the	peptides,	b)	the	peptides	
may	 be	 being	 degraded	 in	 lysosomes	 releasing	 fluorescein-labelled	 fragments	 with	 no	
KDM4A/KDM4C	inhibitory	activity	into	the	cytosol	and	nucleus,	or	c)	the	fluorescein	tagged	
peptides	 are	 present	 in	 the	 cytosol	 but	 unable	 to	 bind	 to	 the	 target	 because	 of	 local	
sequestration	 (e.g.	 through	 binding	 to	 abundant	 cellular	 RNA	 as	 a	 result	 of	 charge	
interactions).	 	 Indeed,	 the	 overall	 explanation	 may	 be	 a	 combination	 of	 these	 factors.			
Importantly,	 however,	 these	 findings	 demonstrate	 that	 the	 use	 of	 fluorescent	 labels	 to	
assess	cellular	uptake	of	peptides	(a	frequently	used	technique)	may	be	misleading	in	some	
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circumstances.	 Assays	which	 use	 substantially	 smaller	 chemical	 tags,	 such	 as	 the	 recently	
described	chloroalkane	penetration	assay	may	give	superior	results	in	this	respect.14	
In	summary,	using	a	RaPID-based	approach	to	peptide	screening	we	have	partially	defined	
the	 structure	 activity	 relationship	 of	 the	 potent	 KDM4A/KDM4C	 inhibitor	 CP2.	 	 In	 the	
process,	we	identified	an	analogue	of	CP2	(CP2f-7)	with	greater	potency	in	in	vitro	inhibition	
assays,	 and	 two	 analogues	 (CP2f-3	 and	 CP2f-4R)	 which	 appeared	 to	 be	 cell	 penetrating	
peptides,	but	which	were	not	active	in	cellular	assays	of	global	methylation.			These	studies	
will	be	useful	 for	 the	design	of	 improved	variants	of	CP2	and	demonstrate	 that	studies	of	
the	 cellular	 uptake	 of	 fluorescently-tagged	 macrocyclic	 peptides	 do	 not	 always	 good	
indicators	of	cellular	activity.	
	
	
4.	Materials	and	Methods	
	
4.1	Expression	of	biotinylated	KDM4A	and	synthesis	of	reagents	for	RaPID	screening.	
Single-site	 C-terminal	 biotinylated	 KDM4A	 was	 expressed	 and	 purified	 as	 previously	
described.5	 	 L-	 and	 D-chloroacety-tyrosine,	 initiator	 tRNA	 and	 the	 recombinant	 translation	
system	were	generated	as	previously	described.15,	16	
	
4.2		Library	construction	and	RaPID	screening.	
Library	 construction	 and	 RaPID	 selection	 of	 macrocyclic	 peptide	 ligands	 to	 KDM4A	 was	
performed	 essentially	 as	 previously	 described.5	 	 In	 brief,	 the	 starting	 DNA	 libraries	 were	
assembled	from	DNA	oligonucleotides	(see	supplementary	information)	by	primer	extension	
and	PCR	using	 Taq	polymerase.	 	 The	 resulting	 library	was	 transcribed	 into	 an	RNA	 library	
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using	 T7	 RNA	 polymerase,	 covalently	 ligated	 to	 a	 puromycin	 moiety	 and	 translated	 into	
peptides	in	a	genetically	reprogrammed	translation	reaction	such	that	L-	or	D-chloroacetyl-
tyrosine	 was	 the	 initiating	 amino	 acid	 in	 place	 of	 formyl-methionine,	 to	 generate	 a	
macrocyclic	peptide	library	in	which	each	peptide	was	covalently	linked	to	its	cognate	RNA.		
For	 the	 first	 round	 of	 selection,	 translation	 was	 conducted	 at	 150	 µL	 scale	 (~1	 x	 1014	
individual	peptide-RNA	fusion	molecules),	and	the	translation	product	was	panned	against	
200	 nM	 biotinylated-KDM4A	 immobilised	 on	 streptavidin-coated	 Dynabeads	 (Life	
Technologies)	for	30	min	at	4oC.		After	washing,	bound	peptide-RNA	fusions	were	recovered	
from	the	beads	by	heating	to	95oC	for	5	min	and	an	enriched	DNA	library	was	generated	by	
PCR	and	used	to	generate	the	RNA	library	for	the	subsequent	round	of	selection.	 	For	the	
second,	 and	 subsequent,	 rounds,	 translation	 was	 conducted	 at	 2.5	 µL	 scale	 (~3	 x	 1012	
individual	peptide-RNA	 fusion	molecules),	and	 the	peptide-RNA	 fusion	 library	was	panned	
against	streptavidin	coated	Dynabeads	in	the	absence	of	KDM4A	3	x	30	min	at	4oC	prior	to	
panning	 against	 KDM4A	 as	 described	 above.	 	 Sequencing	 of	 the	 final	 DNA	 library	 was	
performed	using	a	MiSeq	sequencer	(Illumina)	according	to	the	manufacturer’s	instructions.	
	
4.3		Peptide	synthesis	
All	peptides	were	synthesised	at	25	µmol	scale	using	standard	Fmoc	HBTU/HOBt	chemistry	
on	a	Syro	automated	synthesiser	(Biotage)	or	Fmoc	DIC/Oxyma	chemistry	on	a	Liberty	Blue	
automated	synthesiser	(CEM	corporation)	using	NovaPEG	rink	amide	resin	(Merck	Millipore).		
Chloroacetylation	 of	 the	 final	 product	 was	 performed	 using	 chloroacetic	 acid	 N-
hydroxysuccinamide	 ester	 on	 resin	 as	 previously	 described3,	 5,	 7,	 cleaved	 from	 the	
resin/deprotected,	 cyclized	under	basic	 conditions,	purified	by	HPLC	and	purity	 confirmed	
by	 MALDI-TOF	 MS	 (Supplementary	 Table	 1).	 	 For	 fluorescein	 labelling,	 a	 selectively	
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deprotectable	 Lys(Mmt)	 residue	 was	 included	 downstream	 to	 the	 cyclizing	 Cys	 residue;	
following	synthesis,	Mmt	decoupling	was	performed	with	1%	trifluoroacetic	acid/DCM	and	
the	 resulting	 free	 amine	 was	 coupled	 to	 3	 eq.	 fluorescein-N-hydroxysuccinamide	 ester	
(ThermoFisher	Scientific)	under	basic	conditions	 for	3	hours.	 	Fmoc-protected	amino	acids	
were	purchased	from	Merck	Millipore,	 Japan,	except	 for	Fmoc-N-methyl-isoleucine,	Fmoc-
N-methyl-valine,	Fmoc-N-methyl-cysteine,	Fmoc-D-alanine	and	Fmoc-4-fluorophenylalanine,	
which	were	purchased	from	Watanabe	Chemical	Industries,	Japan.	
	
4.4		Confocal	microscopy	
MCF7	 cells	 grown	 in	 Dulbecco’s	 Modified	 Eagle’s	 Medium	 containing	 10%	 foetal	 bovine	
serum	(FBS)	in	glass-bottomed	petri	dishes	were	stained	with	10	µM	peptide	for	3	hours	and	
100	nM	LysoTracker	Red	DND-99	(ThermoFisher	Scientific)	and	1	µg/mL	Hoechst	33342	for	
30	min	at	37oC,	then	washed	with	phosphate	buffered	saline	containing	1%	FBS	and	imaged	
on	a	TCS	SP5	Laser	Scanning	Confocal	Microscope.		Image	analysis	was	performed	using	the	
Fiji	 distribution	 of	 ImageJ17	 to	 determine	 colocalization	 of	 lysosomal	 and	 peptide	 staining	
(Pearson’s	r)	and	extent	of	intracellular	peptide	distribution	(%	area	above	threshold).			
	
4.5	KDM4A	and	KDM4C	in	vitro	 inhibition	assay	and	immunofluorescence	analysis	of	lysine	
methylation.	
AlphaScreen	 demethylation	 assays	 for	 KDM4s	 were	 carried	 out	 as	 described.18	 	 Cellular	
immunofluorescence	assays	were	performed	as	previously	described.5	 	 In	brief,	HeLa	cells	
were	 transfected	with	plasmids	encoding	a	 FLAG-tagged	 full	 length	KDM4A	using	Fugene.	
After	 4	hours,	 transfection	 reagents	were	 removed	and	 the	 cells	were	 treated	with	 serial	
dilutions	of	compounds	in	0.5%	DMSO	for	24hrs.		Cells	were	fixed,	blocked	and	stained	with	
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anti-FLAG	 (Sigma	 F7425)	 and	 anti-H3K9me3	 (Ab8898,	Abcam)	 antibodies	 (overnight,	 4°C).	
The	 secondary	 antibodies	 were	 Alexa	 488	 anti-mouse	 and	 Alexa	 594	 anti-rabbit	 (Life	
Technologies).	After	nuclear	staining	with	DAPI,	cells	were	imaged	at	10	x	magnification	on	
the	 Operetta	 High	 Contents	 Imaging	 system	 (PerkinElmer)	 and	 image	 analysis	 was	
performed	using	the	Columbus	software	(PerkinElmer).	H3K9me3	 levels	were	analysed	for	
cells	overexpressing	high	levels	of	KDM4A.		
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